Esophagitis: Difference between revisions

No edit summary
Line 3: Line 3:


==Clinical Features==
==Clinical Features==
*Odynophagia and/or dysphagia
*Odynophagia and/or [[dysphagia]]
**Commonly causes dehydration
**Commonly causes [[dehydration]]
*[[Chest pain]]
*[[Chest pain]]
*Nausea  
*[[Nausea]]
*Dyspepsia
*[[Dyspepsia]]


==Differential Diagnosis==
==Differential Diagnosis==
Line 22: Line 22:


==Management==
==Management==
*PPI for GERD-induced esophagitis
*[[PPI]] for [[GERD]]-induced esophagitis
*IV Fluids for dehydration
*[[IV fluids]] for dehydration
*Candidal Infection<ref>Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD. Clin Infect Dis. 2016 Feb 15;62(4):e1-50. doi: 10.1093/cid/civ933. Epub 2015 Dec 16.</ref>
*[[esophageal candidiasis|Candida infection]]<ref>Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD. Clin Infect Dis. 2016 Feb 15;62(4):e1-50. doi: 10.1093/cid/civ933. Epub 2015 Dec 16.</ref>
**Fluconazole: 200mg PO loading dose x1 followed by 100-200 mg PO for 7-14 days
**[[Fluconazole]]: 200mg PO loading dose x1 followed by 100-200 mg PO for 7-14 days


==Disposition==
==Disposition==

Revision as of 20:42, 29 September 2019

Background

  • Inflammation of the esophagus

Clinical Features

Differential Diagnosis

Esophagitis Types

Evaluation

Work-Up

  • CBC
  • CMP
  • Consider HIV workup if unknown causation, risk factors

Evaluation

  • Generally clinical diagnosis in ED (requires EGD for conclusive diagnosis)

Management

Disposition

  • Admit if unable to tolerate PO or if underlying immunosuppression (e.g. HIV)

See Also

References

  1. Clinical Practice Guideline for the Management of Candidiasis: 2016 Update by the Infectious Diseases Society of America. Pappas PG, Kauffman CA, Andes DR, Clancy CJ, Marr KA, Ostrosky-Zeichner L, Reboli AC, Schuster MG, Vazquez JA, Walsh TJ, Zaoutis TE, Sobel JD. Clin Infect Dis. 2016 Feb 15;62(4):e1-50. doi: 10.1093/cid/civ933. Epub 2015 Dec 16.